The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients
about
Microbiota and chronic inflammatory arthritis: an interwoven linkMesalazine preparations for the treatment of ulcerative colitis: Are all created equal?Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis.Sulphasalazine-induced cerebral lupus erythematosusSulfasalazine: a potent and specific inhibitor of nuclear factor kappa BPatient compliance and outcomes.Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease.Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel diseaseCirculating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitisSulphasalazine and male infertility: reversibility and possible mechanismOptimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.An oral preparation to release drugs in the human colon.Kinetics of 5-aminosalicylic acid after jejunal instillation in man.Molecular mechanisms of sulfasalazine-induced T-cell apoptosisN-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel diseaseMedical treatment of ulcerative colitisPenta-O-galloyl-β-D-glucose ameliorates inflammation by inhibiting MyD88/NF-κB and MyD88/MAPK signalling pathways.Pharmacogenomics in the treatment of inflammatory bowel disease.Detection of human intestinal bacterial overgrowth by sulfasalazine.Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets.The relapse-preventing effect of methyl-salazosulphapyridine compared to salazosulphapyridine during long-term treatment of ulcerative colitis. A double-blind controlled trial.Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).Influence of gut microflora on bioavailability.Prostaglandin synthetase activity in acute ulcerative colitis: effects of treatment with sulphasalazine, codeine phosphate and prednisolone.The effect of salicylazosulphapyridine (sulphasalazine) on male fertility. A review.Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease.Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine.Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis.Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine.The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects.The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.Increased suppressor cell activity in inflammatory bowel disease.Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.Intrarectal administration of 5-aminosalicylic acid to rabbits and dogs.Infectious Agents and Inflammation: The Role of Microbiota in Autoimmune Arthritis.5-aminosalicylic acid improves lipid profile in mice fed a high-fat cholesterol diet through its dual effects on intestinal PPARγ and PPARα.Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.The Pharmacokinetics of Sulphasalazine in Young and Elderly Patients with Rheumatoid ArthritisA Modified Colorimetric Assay for Free and N4-Acetylated Sulfapyridine in Serum and Saliva after Sulfasalazine Administration
P2860
Q26739010-362C7ECD-3EFA-43C1-9581-C064C0B7F26CQ26777634-9A2FA1C6-7CF7-4846-8C69-F1AC80B017CEQ28323157-0D8EDEA4-CF92-4CFB-A449-EF2D9C084FF9Q28365760-D7C4098E-9E29-4E72-8619-CFFE83B24459Q28379350-9C975BA6-4C9F-4CAC-B607-039583DBF739Q33641583-062AC3AF-C3BE-4AAB-87A7-6F054DEAAE87Q34447391-0C163D9C-9648-49D3-AF54-9CE8230EA002Q34477152-DD82F19B-4E8C-475C-B580-547B4B6AC2BBQ34493372-C6BF8CB7-E504-4C85-87CD-A6DF67BD229CQ34493755-85A662B8-608D-44E1-9F0D-8A24A1A42231Q34496962-EF4289BF-ECC3-4DD6-99AB-5949415A9AC5Q34511869-5A425A4E-FFBD-4EF4-87FA-DF692F30522AQ34514156-EE45849B-26E5-451A-A992-C4696D568D99Q35044669-02FECA19-AC7E-466E-A253-0B022C43C0F3Q37133431-EE44C400-0EB1-42C1-BBEE-BFC5C659C854Q37427481-3D4E40D4-7DA5-4EFB-A2A4-106E95BB56B4Q37630375-659757F4-0F99-4FA8-9F98-B6AB69896EE9Q37710516-DFA13BAD-9150-42C6-9981-1E8CFBF3A2C8Q39222461-6FBE6FEA-EFED-48D2-B91B-855D6E89AB5CQ39234076-47582133-8463-498C-BD2D-D2F08427E8DBQ39250069-EAD6EBA2-05D6-403B-B402-D360F28ADDFEQ39252422-EC09DEF2-64B7-443D-B55F-870043517F0DQ39274520-2AEF4F9C-449C-463E-8C3D-98DB0B324A0FQ39281655-7F2988EC-F38D-47DE-BA92-1938EB4BDE9DQ39459955-800DBC51-27D0-4945-A907-1F660D399698Q40845749-E8044451-B6B7-4876-98F9-680304517DE5Q40911348-F294456D-685D-4B25-B02C-1604EB40996CQ41150439-74FD8841-ABEB-4D50-B470-82A9E0BBFB52Q41679681-D26C628F-5CEF-4959-B8AA-AE31F15D016AQ42008549-5B75748D-56C5-4D80-9C6D-B64418922978Q42046198-8372186D-20DA-4661-A9A3-373BF2F469AEQ43241349-55908A0F-09D9-42BA-BBBE-C779921B80E0Q43255584-8782F138-CD15-4724-BC14-D8462B1CA9D7Q43514773-27EE9732-DBAC-4E3C-8E73-6C55B2F7FACEQ44053183-9ED2D2A0-E126-474D-8AA6-88E24B5B9C93Q47547409-592DCAE8-1A74-4177-86B3-36C8DE6722CCQ48203795-1B4469FB-F38F-4EBD-A342-33B708261E06Q48899356-C3EE5283-4A0D-4961-AEBC-24533BECF033Q57913843-9DA9D483-78CA-4A35-B8E2-88205F07E5C5Q58148279-AF5B36AA-C91B-46CC-8B2E-5363F4662BF2
P2860
The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients
description
1973 nî lūn-bûn
@nan
1973年の論文
@ja
1973年論文
@yue
1973年論文
@zh-hant
1973年論文
@zh-hk
1973年論文
@zh-mo
1973年論文
@zh-tw
1973年论文
@wuu
1973年论文
@zh
1973年论文
@zh-cn
name
The metabolism of salicylazosu ...... nse to treatment in inpatients
@en
type
label
The metabolism of salicylazosu ...... nse to treatment in inpatients
@en
prefLabel
The metabolism of salicylazosu ...... nse to treatment in inpatients
@en
P2093
P2860
P356
P1433
P1476
The metabolism of salicylazosu ...... nse to treatment in inpatients
@en
P2093
P2860
P304
P356
10.1136/GUT.14.8.631
P407
P577
1973-08-01T00:00:00Z